

December 14, 2022

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

We refer to the captioned Regulation.

This is to inform that the Board of Directors at its Meeting held today i.e., December 14, 2022, considered and transacted *inter alia* the following business:

1. Noted the Resignation of Mr. Gagandeep Singh Bedi (DIN: 07844333) from the Office of Managing Director and also as Director of the Company with effect from the closing of business hours on December 31, 2022. The details of the resignation are enclosed below as ‘**Annexure- A**’.
2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Sanjeev Panchal (DIN: 09823879), as Additional Director and also as Managing Director of the Company for a period of three (3) years with effect from January 1, 2023 subject to the approvals of the Members of the Company through Postal Ballot and Central Government, if so needed. Brief details of Mr. Sanjeev Panchal are enclosed below as ‘**Annexure- B**’.

Kindly take the above on your records.

Thanking you,

Yours faithfully,
For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Annexure A

Resignation of Mr. Gagandeep Singh Bedi (DIN: 07844333) from the Office of Managing Director and also as Director of the Company:

Sl. No	Particulars	Details
1	Reason for change Viz. appointment, resignation, removal, death or otherwise	Consequent to transfer to a new position within AstraZeneca Group.
2	Date of Appointment/ Cessation/ Term of appointment	Effective date of Cessation: From the closing of business hours on December 31, 2022.
3	Brief Profile	Not Applicable.
4	Disclosure of Relationships between Directors	Not Applicable.
5	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Not Applicable.

Annexure B

Appointment of Mr. Sanjeev Panchal (DIN: 09823879) as Additional Director and also as Managing Director of the Company:

Sl. No	Particulars	Details
1	Reason for change Viz. appointment, resignation, removal, death or otherwise	Based on transfer of Mr. Gagandeep Singh Bedi to another global position, this appointment was approved. Appointment of Mr. Sanjeev Panchal (DIN: 09823879) as Additional Director and also as Managing Director of the Company with effect from January 1, 2023.
2	Date of Appointment/ Cessation/ Term of appointment	Effective date of appointment: January 1, 2023. Term: For a period of three (3) years commencing from January 1, 2023 subject to the requisite approvals of the Members and of Central Government, if so needed.
3	Brief Profile	Mr. Sanjeev Panchal is a Science graduate (BSc) and he holds an MBA and Doctorate in Business Administration (PhD). He also has professional Diplomas in International Business and HRM. He had joined AstraZeneca Pharma India Limited in February 2003 as Brand Associate and progressed through several positions in India, Indonesia, Asia Pacific and the

		<p>International region, based in Singapore and the United Kingdom (UK). Prior to his current role as CP Malaysia, Mr. Sanjeev was the Director for CVRM Commercial and CVMD Brand - International based out in United Kingdom (UK) between May 2017 to September 2019. Before his assignment to UK, Mr. Sanjeev played critical leadership roles in India such as BU Head for Brilinta and Interim BU Head Respiratory during 2014 to 2017. Prior to his BU Head role, he was managing portfolios of Sales & Marketing Director for Brilinta and Marketing Director – CV till 2010. Mr. Sanjeev was in an International assignment to Singapore as a Regional Marketing Manager – Respiratory & GI, Asia Pacific between 2009 to 2010. He was also an Interim Marketing Director for AZ Indonesia for 3 months International assignment in 2010.</p> <p>In his role as a Country President of Malaysia, Mr. Sanjeev has significantly transformed the business and guided the team to return the company to growth, growing almost double the market at 25% in 2022. AstraZeneca Malaysia now ranks #3 overall and #2 among MNCs.</p>
4	Disclosure of Relationships between Directors	Mr. Sanjeev Panchal is not related to any of the Directors of the Company.
5	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Mr. Sanjeev Panchal is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.